Study on biologic activity for membrane of normal bone marrow cells with infection of epidemic hemorrhagic fever virus

2000 ◽  
Vol 20 (4) ◽  
pp. 322-323
Author(s):  
Zhang Jian’ao ◽  
Zeng Linglan ◽  
Luo Duande ◽  
Cai Shuqing ◽  
Liu Wei ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Hemorrhagic Fever ◽  
Fever Virus ◽  
Normal Bone Marrow ◽  
Hemorrhagic Fever Virus ◽  
Normal Bone ◽  
Biologic Activity ◽  
Marrow Cells

Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response

2009 ◽  
Vol 33 (1) ◽  
pp. 170-173 ◽  
Author(s):  
Fermin M. Sanchez-Guijo ◽  
Jesus M. Hernandez ◽  
Eva Lumbreras ◽  
Patricia Morais ◽  
Carlos Santamaría ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Chronic Myeloid Leukemia ◽  
Imatinib Mesylate ◽  
Myeloid Leukemia ◽  
Bone Marrow Cells ◽  
Cytogenetic Response ◽  
Normal Bone Marrow ◽  
Normal Bone ◽  
Complete Cytogenetic Response ◽  
Marrow Cells

Cancer-induced cytolysis of normal bone marrow cells

Nature ◽  
1977 ◽  
Vol 265 (5596) ◽  
pp. 736-737 ◽  
Author(s):  
STANLEY ZUCKER ◽  
RITA LYSIK
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Normal Bone Marrow ◽  
Normal Bone ◽  
Marrow Cells

in vitro studies with melphalan and pediatric neoplastic and normal bone marrow cells

1986 ◽  
Vol 37 (6) ◽  
pp. 819-823 ◽  
Author(s):  
Diana A. Worthington-White ◽  
John R. Graham-Pole ◽  
Susan A. Stout ◽  
Christopher M. Riley
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
In Vitro Studies ◽  
Normal Bone Marrow ◽  
Normal Bone ◽  
Marrow Cells

Antitumor activity of normal bone marrow cells

1995 ◽  
Vol 120 (2) ◽  
pp. 826-828
Author(s):  
I. V. Avdeev ◽  
V. I. Seledtsov ◽  
I. V. Prokopenko ◽  
G. V. Seledtsova ◽  
V. A. Kozlov
Keyword(s):  
Bone Marrow ◽  
Antitumor Activity ◽  
Bone Marrow Cells ◽  
Normal Bone Marrow ◽  
Normal Bone ◽  
Marrow Cells

Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells

1992 ◽  
Vol 81 (2) ◽  
pp. 145-152 ◽  
Author(s):  
Jean-Pierre Marie ◽  
Nathalie A. Brophy ◽  
Mohamed N. Ehsan ◽  
Yukoh Aihara ◽  
Named A. Mohamed ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Multidrug Resistance ◽  
Resistance Gene ◽  
Bone Marrow Cells ◽  
Normal Bone Marrow ◽  
Multidrug Resistance Gene ◽  
Normal Bone ◽  
Mdr1 Mrna ◽  
Marrow Cells

Expression of MDR1 by Normal Bone Marrow Cells and its Implication for Leukemic Hematopoiesis

1995 ◽  
Vol 16 (5-6) ◽  
pp. 419-424 ◽  
Author(s):  
Johannes Drach ◽  
Shourong Zhao ◽  
Doris Drach ◽  
Martin Körbling ◽  
Heike Engel ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Normal Bone Marrow ◽  
Normal Bone ◽  
Marrow Cells

Use of 5-Fold Staining for Multiparameter Flow Cytometry-Based Quantification of Minimal Residual Disease in Acute Myeloid Leukemia Results in Improved Sensitivity.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2025-2025
Author(s):  
Wolfgang Kern ◽  
Daniela Voskova ◽  
Claudia Schoch ◽  
Wolfgang Hiddemann ◽  
Susanne Schnittger ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Residual Disease ◽  
Multiparameter Flow Cytometry ◽  
Normal Bone Marrow ◽  
Prognostic Information ◽  
Normal Bone ◽  
Triple Staining ◽  
Marrow Cells

Abstract The quantification of minimal residual disease (MRD) by multiparameter flow cytometry (MFC) using triple staining has been shown to yield prognostic information independent of other parameters in patients with acute myeloid leukemia (AML). Due to the immunophenotypic heterogeneity of AML the application of 5-fold staining may result in a better characterization of the leukemia-associated aberrant immunophenotype (LAIP) and thus in an improved sensitivity of the method as compared to triple staining. We analyzed bone marrow samples from 114 patients with newly diagnosed and untreated AML by MFC using a comprehensive antibody panel with 5-fold combinations. Sensitivity was estimated by quantification of LAIP-positive cells for each LAIP in 18 normal bone marrow samples. In each patient at least one LAIP was identified (total, 203 LAIPs). The LAIPs were present on a median of 15.88% of the bone marrow cells at diagnosis (range, 2.11% to 79.64%). The median number of normal bone marrow cells displaying the LAIPs ranged from 0.001% to 0.065% (median, 0.010%). As a result, the logarithmic difference (LD) in LAIP-positive cells between leukemic and normal bone marrow amounted to a median of 3.33 (range, 1.96 to 4.88). Similarly, if only the most sensitive LAIP was considered for each patient the median frequencies of LAIP-positive cells were 14.07% (range, 2.11% to 77.57%) in leukemic bone marrow and 0.010% (range, 0.001% to 0.065%) in normal bone marrow. Importantly, however, in this setting the resulting LD amounted to a median of 3.45 (range, 1.96 to 4.88). In order to estimate the impact of applying 5-fold staining on the sensitivity the information of each of the applied colors was skipped once while the results of the other four colors, respectively, were used. Skipping one color resulted in an increase of LAIP-positive normal bone marrow cells (median, 0.050%; range, 0.001% to 3.6%) while the percentages of LAIP-positive leukemic cells changed only marginally (median, 22.65%; range, 2.25% to 90.06%). The gain in LD by applying 5-fold staining in comparison to 4-fold staining amounted to a median of 0.58 (maximum gain, 3.14). In 32 patients a total of 120 follow-up samples have been analyzed appyling the combination of antibodies that allowed the best LAIP definition. The LD from diagnosis to follow-up amounted to a median of 2.82 (range, 0.77 to 4.82). Clinical follow-up data is available in 26 of these 32 patients. MRD assessment after completion of consolidation therapy has been performed in 15 patients. The median LD between diagnosis and follow-up assessment is 2.84 (range, 1.07 to 4.33). Separating patients according to this median LD identified a group of patients with no relapses yet (LD >2.84) while patients with an LD <2.84 had an event-free survival of only 50% at one year (p=0.075). These data confirm that flow cytometrically-based assessment of MRD is feasible in AML and results in prognostic information. It is suggested that the application of 5-fold staining significantly improves the sensitivity and thereby the overall accuracy of the method.

High Frequency of Molecular Remissions (m-CR) in Multiple Myeloma Patients Achieving a Hematologic Complete Remission (CR) on Total Therapy II (TT-2).

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 933-933
Author(s):  
Guido Tricot ◽  
Matteo Carrabba ◽  
Bart Barlogie ◽  
Joshua Epstein ◽  
John Shaughnessy ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Plasma Cells ◽  
Bone Marrow Cells ◽  
Residual Disease ◽  
Detection Threshold ◽  
M Protein ◽  
Pcr Analysis ◽  
Normal Bone Marrow ◽  
Normal Bone ◽  
Marrow Cells

Abstract TT-2 represents a very intensive treatment approach for newly diagnosed myeloma patients consisting of hematopoietic growth factor-dependent induction therapy (VAD, DCEP, CAD, DCEP); followed by melphalan 200 mg/m2-based tandem autotransplant; 4 quarterly consolidation chemotherapy cycles with D-PACE; and interferon alpha maintenance with added dexamethasone pulsing during the first year. A stringently defined hematologic CR (immunofixation negative, normal bone marrow aspirate and biopsy, and absence of a light-chain restricted aneuploid population of bone marrow plasma cells by DNA/cIg flow cytometry) was obtained in 48% of the first 446 patients enrolled on TT-2. A CR defined as such probably reflects a detection threshold of 108–109 tumor cells. CDR3-PCR to evaluate minimal residual disease (MRD) in myeloma has revealed m-CR in 50% of 40 reported allotransplant cases compared to approximately 15% among 75 reported autotransplants myeloma. We evaluated the frequency of m-CR in 20 TT-2 patients with a qualitative PCR for CDR3, which can detect 1 myeloma cell in 105–106 normal bone marrow cells (Corradini et al. J Clin Oncol 1999, 17: 208). CDR3 probes were generated from RNA of CD138 immunogenetic bead-purified plasma cells obtained at diagnosis. Light-density (<1.077 g/cm3) bone marrow cells served as the source of DNA post-therapy to assess MRD. The quality of DNA was determined by amplification of the p53 exon 6 sequence on all CDR3-PCR negative cases. At the time of CDR3-PCR analysis, 13 patients were in hematologic CR, 1 in near CR (immunofixation positivity as the only evidence of disease), 4 in partial remission (PR) (bone marrow < 5% plasma cells, decrease in serum M protein ≥ 75% and in urine M protein ≥ 90%) and two had less than a PR. Four patients were tested for MRD prior to the first transplant (2 < PR, 1 PR, 1 CR), two prior to the second transplant (2 PR) and 14 at a median of 21 months (range 6 months to 2 years) after the second transplant (12 CR, 1 near CR, 1 PR). Six of the 13 CR patients had abnormal metaphase cytogenetics at diagnosis, including 5 with deletion of chromosome 13. A m-CR was observed in 10/13 (77%) hematologic CR patients, including 4/6 with abnormal cytogenetics and 6/7 with normal cytogenetics. P53 exon 6 amplification was seen in all patients who were CDR3-PCR negative. Not unexpectedly, all seven patients failing to achieve a stringently defined hematologic CR had persistent disease as assessed by CDR3-PCR. Our results suggest that high intensity therapy as applied in TT-2 can indeed achieve a more marked tumor cytoreduction as reflected by a higher m-CR rate than previously reported with autotransplantation also in patients with baseline abnormal metaphase cytogenetics, and that the m-CR rate appears to be at least equivalent to that observed after allotransplantation. It remains to be shown whether achieving a m-CR will result in prolonged survival and a potential of cure in myeloma as has been shown convincingly for other hematologic malignancies. An additional 35 hematologic CR patients have samples available for CDR3-PCR analysis so that, at the time of presentation, a more definitive assessment of TT-2’s potential to effect a m-CR can be presented.

BIOCHEMICAL, PATHOLOGICAL, AND CLINICAL RESPONSE TO TRANSPLANTATION OF NORMAL BONE MARROW CELLS INTO ACID SPHINGOMYELINASE-DEFICIENT MICE1

1998 ◽  
Vol 65 (7) ◽  
pp. 884-892 ◽  
Author(s):  
Silvia R.P. Miranda ◽  
Shai Erlich ◽  
Victor L. Friedrich ◽  
Mark E. Haskins ◽  
Shimon Gatt ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Clinical Response ◽  
Bone Marrow Cells ◽  
Acid Sphingomyelinase ◽  
Normal Bone Marrow ◽  
Normal Bone ◽  
Marrow Cells

scholarly journals Effects of hoechst 33342 on survival and growth of two tumor cell lines and on hematopoietically normal bone marrow cells

Cytometry ◽  
1982 ◽  
Vol 3 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Jerrold Fried ◽  
Jeffrey Doblin ◽  
Shigeru Takamoto ◽  
Amaury Perez ◽  
Herbert Hansen ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Tumor Cell ◽  
Cell Lines ◽  
Bone Marrow Cells ◽  
Normal Bone Marrow ◽  
Tumor Cell Lines ◽  
Hoechst 33342 ◽  
Normal Bone ◽  
Survival And Growth ◽  
Marrow Cells
Sign in / Sign up

Export Citation Format

Share Document